ARK Innovation ETF vs Tilray Brands Inc — how do they compare? ARK Innovation ETF trades at $80.8, while Tilray Brands Inc trades at $4.67 (market cap $649.42M). The key difference: ARK Innovation ETF is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | TLRY | |
|---|---|---|
52-Week High | $92.50 | $21.00 |
52-Week Low | $63.52 | $3.88 |
Market Cap | — | $649.42M |
Sector | — | Health |
Enterprise Value | — | $816.55M |
Signals from Pluang's Aura AI — not financial advice
ARKK trades at $81.51, up 1.3% on the day, with technical indicators showing a bullish trend from moving averages but overbought short-term RSI. The ETF's performance remains challenged by high concentration in speculative growth stocks like Tesla and SpaceX, with no fundamental ratios provided. Recent news highlights Cathie Wood's continued bets on AI and space innovation amid criticism of fees and underperformance versus the S&P 500.
Outlook is cautious due to reliance on a few volatile holdings and premium fees; risks include growth deceleration and market sentiment shifts. Opportunities exist if disruptive bets pay off, but investor patience is required amid potential downside volatility.
TLRY trades at $4.71, up 6.56% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $821M in 2025, yet the company posted a net loss of -$2.19B, reflecting profitability challenges. Recent news highlights growth initiatives, including a partnership with Wolverhampton Wanderers and a new THC pouch launch. The stock remains volatile, with a low P/S of 0.58 and P/B of 0.4, suggesting potential undervaluation amid ongoing losses.
Outlook is cautious; TLRY's path to profitability hinges on revenue growth and cost management. Risks include persistent losses, high debt, and regulatory uncertainty. Analyst consensus is mixed, with 25% buy ratings but 65% hold, indicating skepticism. Investors should weigh growth potential against financial instability and market volatility.
Trailing returns across standard periods
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →